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A BS TR AC T
BACKGROUND
The long-term prognosis for older patients with mantle-cell lymphoma is poor. 
Chemoimmunotherapy results in low rates of complete remission, and most pa-
tients have a relapse. We investigated whether a fludarabine-containing induction 
regimen improved the complete-remission rate and whether maintenance therapy 
with rituximab prolonged remission.
METHODS
We randomly assigned patients 60 years of age or older with mantle-cell lymphoma, 
stage II to IV, who were not eligible for high-dose therapy to six cycles of rituximab, 
fludarabine, and cyclophosphamide (R-FC) every 28 days or to eight cycles of ritux-
imab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) every 
21 days. Patients who had a response underwent a second randomization to main-
tenance therapy with rituximab or interferon alfa, each given until progression.
RESULTS
Of the 560 patients enrolled, 532 were included in the intention-to-treat analysis for 
response, and 485 in the primary analysis for response. The median age was 70 years. 
Although complete-remission rates were similar with R-FC and R-CHOP (40% and 
34%, respectively; P = 0.10), progressive disease was more frequent with R-FC (14%, vs. 
5% with R-CHOP). Overall survival was significantly shorter with R-FC than with 
R-CHOP (4-year survival rate, 47% vs. 62%; P = 0.005), and more patients in the R-FC 
group died during the first remission (10% vs. 4%). Hematologic toxic effects oc-
curred more frequently in the R-FC group than in the R-CHOP group, but the fre-
quency of grade 3 or 4 infections was balanced (17% and 14%, respectively). In 274 of 
the 316 patients who were randomly assigned to maintenance therapy, rituximab 
reduced the risk of progression or death by 45% (in remission after 4 years, 58%, 
vs. 29% with interferon alfa; hazard ratio for progression or death, 0.55; 95% con-
fidence interval, 0.36 to 0.87; P = 0.01). Among patients who had a response to 
R-CHOP, maintenance therapy with rituximab significantly improved overall sur-
vival (4-year survival rate, 87%, vs. 63% with interferon alfa; P = 0.005).
CONCLUSIONS
R-CHOP induction followed by maintenance therapy with rituximab is effective for 
older patients with mantle-cell lymphoma. (Funded by the European Commission 
and others; ClinicalTrials.gov number, NCT00209209.)
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Patients with mantle-cell lymphoma typically present with extensive disease and involvement of multiple lymph nodes as well 
as the spleen, bone marrow, blood, and gastroin-
testinal tract. The median age at diagnosis is 
about 65 years.1,2 Standard therapy for these pa-
tients consists of chemotherapy (e.g., the CHOP 
regimen, consisting of cyclophosphamide, doxoru-
bicin, vincristine, and prednisone) combined with 
the anti-CD20 monoclonal antibody rituximab 
(e.g., R-CHOP).2-4 Only a minority of patients have 
a complete remission, and relapse or progression 
usually occurs within 2 to 3 years, resulting in an 
overall survival of less than 5 years.
To improve this grim prognosis, we attempted 
to establish a more effective induction therapy, 
resulting in an increased rate of complete remis-
sion, and better postinduction strategies, such as 
maintenance therapy, that would prolong the du-
ration of remission. Several previous studies have 
investigated fludarabine-containing regimens, 
which showed high efficacy in follicular lympho-
ma and relapsed mantle-cell lymphoma.4-7 A trial 
of a combination of fludarabine, cyclophospha-
mide with or without mitoxantrone, and ritux-
imab showed promising results.8 Considering 
the risk of cardiac toxic effects in older patients, 
treatments that excluded anthracyclines were 
particularly attractive.
Maintenance therapy with interferon alfa 
showed a tendency toward prolongation of pro-
gression-free survival in patients with mantle-cell 
lymphoma and was therefore considered standard 
therapy in a previous trial.9 Maintenance therapy 
with rituximab had significantly improved the 
duration of response in patients with relapsed 
follicular lymphoma or mantle-cell lymphoma10 
and seemed to be a promising alternative, given 
the strong CD20 expression on mantle-cell-lym-
phoma cells.
Therefore, in 2004, we initiated a double-ran-
domized intergroup trial with two objectives. 
First, we compared the rates of response to an 
induction regimen consisting of fludarabine, 
cyclophosphamide, and rituximab (R-FC) and an 
induction regimen with R-CHOP. Second, we stud-
ied the duration of remission; patients who had a 
response were randomly assigned to maintenance 
therapy with rituximab or interferon alfa (see 
Fig. S1 in the Supplementary Appendix, available 
with the full text of this article at NEJM.org).
ME THODS
CHARACTERISTICS OF THE PATIENTS
Eligible patients had newly diagnosed, histologi-
cally confirmed mantle-cell lymphoma,1 Ann Ar-
bor stage II to IV; were 66 years of age or older or 
were 60 to 65 years of age if they were ineligible 
for high-dose treatment; and had an Eastern Co-
operative Oncology Group performance status of 
2 or less (with 0 indicating asymptomatic, 1 symp-
tomatic but ambulatory, and 2 symptomatic and 
in bed less than half the day). Pathological findings 
were centrally reviewed by the Pathology Panel of 
the European Mantle Cell Lymphoma Network.11 
Patients were excluded if they had a leukocyte 
count of less than 2×109 per liter, a platelet count of 
less than 100×109 per liter, a liver-enzyme level 
greater than 3 times the upper limit of the normal 
range, a bilirubin level greater than 2.5 times the 
upper limit of the normal range, or a creatinine 
level greater than 2 times the upper limit of the 
normal range, if these counts or levels were un-
related to mantle-cell lymphoma. Additional ex-
clusion criteria were involvement of the central ner-
vous system, a history of autoimmune cytopenia, 
hypersensitivity to murine antibodies, other can-
cers, and serious cardiac, pulmonary, neurologic, 
or endocrine disease or other conditions that 
might interfere with adherence to the study.
STUDY PROTOCOL
The study was performed in accordance with the 
updated Declaration of Helsinki, and all patients 
provided written informed consent. Both ran-
domizations were performed centrally at the data 
center of the European Mantle Cell Lymphoma 
Network or at the data center of the Hemato-
Oncology Foundation for Adults in the Nether-
lands (HOVON) and were stratified according to 
study group, age, and the International Prognos-
tic Index12 risk profile. The second randomiza-
tion was also stratified according to the induction 
regimen and the category of response. On behalf 
of the European Mantle Cell Lymphoma Network, 
the first, second, penultimate, and last authors 
designed the study and vouch for the accuracy 
and completeness of the data and analysis and the 
fidelity of the study to the protocol; these authors 
wrote the manuscript and made the decision to 
submit it for publication. The second and penulti-
mate authors gathered and analyzed the data.
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Roche Pharmaceuticals and Schering-Plough 
supplied maintenance medication at no cost but 
played no role in the design or execution of the 
study, the data collection or analysis, or the writ-
ing of the manuscript. The protocol, including the 
statistical analysis plan, is available at NEJM.org.
INDUCTION TREATMENT
Induction therapy consisted of either R-FC or 
R-CHOP open-label chemoimmunotherapy. Ritux-
imab was added to the chemotherapy when the 
count of circulating lymphoma cells was less than 
10×109 per liter. The R-FC regimen consisted of 
rituximab at a dose of 375 mg per square meter 
of body-surface area given intravenously on day 1 
(maximum dose, 750 mg), fludarabine at a dose 
of 30 mg per square meter given intravenously on 
days 1 through 3, and cyclophosphamide at a dose 
of 250 mg per square meter given intravenously 
on days 1 through 3. The regimen was repeated 
at day 29 for six cycles. The R-CHOP regimen 
consisted of rituximab at a dose of 375 mg per 
square meter (maximum dose, 750 mg), cyclophos-
phamide at a dose of 750 mg per square meter, 
doxorubicin at a dose of 50 mg per square meter, 
and vincristine at a dose of 1.4 mg per square 
meter (maximum dose, 2 mg), all given intrave-
nously on day 1, and oral prednisone at a dose of 
100 mg given on days 1 through 5. The regimen 
was repeated at day 22 for eight cycles. If neuro-
logic toxic effects occurred, the dose of vincris-
tine was modified at the physician’s discretion.
Subsequent courses were postponed for 1 week 
if the leukocyte count was less than 4×109 per li-
ter or the platelet count was less than 100×109 per 
liter. Doses of fludarabine, cyclophosphamide, and 
doxorubicin in subsequent cycles were modified 
if myelosuppression was persistent (see the Sup-
plementary Appendix). If progression occurred, 
induction was stopped.
MAINTENANCE TREATMENT
The option to participate in the second random-
ization was offered to patients who had a response 
to the induction regimen, a leukocyte count great-
er than 3×109 per liter, and a platelet count greater 
than 100×109 per liter (or greater than 75×109 per 
liter, according to a protocol amendment in 2009). 
Open-label maintenance therapy started immedi-
ately after the date of the second randomization 
and continued until progression. Rituximab was 
continued at a dose of 375 mg per square meter 
every 2 months. Standard interferon alfa was ad-
ministered subcutaneously at a dose of 3 million 
units three times per week; pegylated interferon 
alfa was administered at a dose of 1 μg per kilo-
gram of body weight per week. If any toxic effect 
of grade 2 or 3 occurred, the dose was reduced by 
30 to 50%; for any toxic effect of grade 4, treat-
ment with interferon alfa was interrupted until re-
covery, then resumed at 50% of the previous dose, 
and gradually increased if serious adverse events 
did not occur.
STAGING PROCEDURES, RESPONSE MONITORING, 
AND END POINTS
Baseline measurements consisted of computed to-
mography (CT) of the neck, chest, abdomen, and 
pelvis, and a trephine biopsy of bone marrow; 
additional investigations were performed if clini-
cally indicated. The response was evaluated accord-
ing to the 1999 consensus criteria13 (see the Sup-
plementary Appendix). CT studies and testing for 
other initially positive findings were repeated at 
midterm (i.e., after four cycles of R-CHOP or three 
cycles of R-FC) and at the end of the induction 
phase. The response to induction chemotherapy 
was determined 4 weeks after the last cycle. Dur-
ing follow-up, response evaluations were per-
formed twice yearly until progression.
The primary prespecified end point for the 
comparison of the induction regimens was the 
rate of complete remission (excluding uncon-
firmed complete remissions). For the primary 
analysis, the response was classified as a pre-
mature stop if the induction regimen was 
stopped either earlier than midterm, in patients 
without progression, or when less than two 
thirds of the cycles had been completed, in 
patients who had a response. The primary pre-
specified end point for the comparison of main-
tenance regimens was the duration of remis-
sion, which was cal culated as the interval from 
the last day of induction therapy until progres-
sion or death from any cause. The secondary end 
points were the overall response rate, the time 
to treatment failure (defined as stable disease, 
relapse, progression, or death) from the start of 
induction therapy, overall survival, and toxic 
effects.
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STATISTICAL ANALYSIS
The overall response rate and the duration of re-
mission were monitored by sequential analyses14 
with planned interim analyses. The study was de-
signed to have 95% power to detect an increase in 
the rate of complete remission from 50% after 
R-CHOP to 65% after R-FC, at a one-sided signifi-
cance level of 5%. For the duration of remission, 
the study was designed to have 95% power to detect 
a 40% reduction in the risk of progression or death 
with rituximab, as compared with interferon alfa, 
at a two-sided significance level of 5%. We calcu-
lated that we would need to enroll a total of 570 
patients (allowing for withdrawals from the study), 
and that a maximum of 240 events, with adjust-
ment for the sequential design (Fig. S2A in the 
Supplementary Appendix), would be needed to 
compare the duration of remission with the two 
maintenance regimens.
As prespecified in the protocol, the primary 
analysis included patients with mantle-cell lym-
phoma of stage II to IV who underwent random-
ization and had started treatment in accordance 
with the randomization result; data for patients 
receiving maintenance therapy who started anoth-
er antilymphoma therapy without progression were 
censored at the time of the protocol violation. All 
secondary efficacy analyses were performed ac-
cording to the intention-to-treat principle, with all 
patients who underwent randomization included 
and protocol violations ignored. For safety analy-
ses, patients were evaluated as treated.
Remission rates and other categorical variables 
were compared by means of Fisher’s exact test; 
time-to-event variables were described with the 
use of Kaplan–Meier estimates and compared with 
use of the log-rank test. P values for sequentially 
monitored end points were reported with adjust-
ment for interim analyses. For the maintenance-
therapy comparison, a potential interacting effect 
by type of induction therapy was explored by 
means of multiple Cox regression. In the case of a 
significant interaction, stratified effects were re-
ported. The calculation of the sample size and the 
sequential monitoring were performed with the 
use of PEST software, version 3 (Applied Statistics 
Department, University of Reading, Reading, Unit-
ed Kingdom). Statistical analysis was performed 
with the use of SAS software, version 9.2 (SAS 
Institute).
R ESULT S
INDUCTION TREATMENT
Between January 2004 and October 2010, a total of 
560 patients from eight countries were randomly 
assigned to chemotherapy with R-CHOP or R-FC; 
532 of these patients were included in the intention-
to-treat analysis and 485 were included in the 
primary analysis (Fig. 1A). Table 1 and Table S1 
in the Supplementary Appendix show the demo-
graphic and clinical characteristics of the patients.
The rate of complete remissions at the end of 
induction therapy was not significantly higher 
after R-FC (98 of 246 patients [40%]) than after 
R-CHOP (81 of 239 [34%]) (P = 0.10 with a one-
sided test, in the primary analysis). The overall 
response rate was lower after R-FC than after 
R-CHOP but the difference was not significant 
(192 of 246 patients [78%] and 206 of 239 [86%], 
respectively; P = 0.06, with adjustment for interim 
analyses), and complete-remission rates, including 
unconfirmed complete remission, were also 
similar (53% and 49%, respectively). The rate of 
progression was higher during R-FC than during 
R-CHOP (14% vs. 5%). The intention-to-treat 
analysis yielded identical results (Table S2 in the 
Supplementary Appendix). After a median follow-
up of 37 months, the time to treatment failure was 
similar with R-FC and R-CHOP (median, 26 and 
28 months, respectively) (Fig. 2A) with a similar 
duration of remission (37 and 36 months, re-
spectively). 
However, the overall survival was significantly 
shorter after R-FC than after R-CHOP (survival rate 
at 4 years, 47% vs. 62%; P = 0.005; hazard ratio for 
death, 1.50; 95% confidence interval [CI], 1.13 to 
1.99) (Fig. 2B). Of the 560 patients, 199 died — 
115 of 280 patients in the R-FC group and 84 of 
280 in the R-CHOP group. Causes of death were 
mainly related to progression of lymphoma (64 
patients in the R-FC group vs. 47 in the R-CHOP 
group). In addition, more patients who received 
R-FC died from infection, as compared with those 
who received R-CHOP (19 vs. 12), or from a sec-
ondary cancer (9 vs. 3). The remaining causes of 
death in the R-FC and R-CHOP groups, respec-
tively, were related to cardiac causes (4 and 9 pa-
tients), pulmonary causes (3 and 2), central 
nervous system bleeding or ischemia (2 and 1), 
leukoencephalopathy (1 and 1), or unknown 
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560 Patients underwent randomization
280 Were assigned to R-CHOP 280 Were assigned to R-FC
6 Did not start treatment
3 Withdrew consent
1 Was lost to follow-up
2 Did not have MCL
3 Did not start treatment
1 Withdrew consent
1 Did not have accept-
able medical center
1 Did not have MCL
277 Started treatment
277 Received R-FC
274 Started treatment
273 Received R-CHOP
1 Received rituximab
7 Had undocumented 
responses
7 Were not staged for 
response, including 1 
who received rituximab
12 Had undocumented 
responses
1 Was lost to follow-up
11 Were not staged for 
response
267 Were included in the intention-
to-treat analysis
265 Were included in the intention-
to-treat analysis
28 Were excluded
13 Did not have MCL
1 Had stage I MCL
14 Stopped treatment early
239 Were included in the primary
analysis
246 Were included in the primary
analysis
316 Underwent randomization
for maintenance therapy
161 Were assigned to interferon alfa 155 Were assigned to rituximab
30 Were excluded
23 Did not start maintenance
therapy
9 Had cytopenia
8 after R-FC
1 after R-CHOP
2 Were lost to follow-up
4 Withdrew
2 Had contraindications
2 Had other reasons
4 Had unknown reasons
2 Did not have MCL
1 Had stage I MCL
4 Started rituximab
12 Were excluded
8 Did not start maintenance
therapy
5 Had cytopenia after R-FC
2 Were lost to follow-up
1 Had unknown reason
4 Did not have MCL
143 Were included in the primary
analysis
131 Were included in the primary
analysis
560 Patients underwent randomization
for induction therapy
244 Did not undergo the second randomization
93 Were not in remission
44 Stopped induction therapy prematurely
29 Had persistent cytopenia
8 Had contraindications
16 Withdrew or were withdrawn by physician
2 Had other reasons 
17 Had unknown reasons 
35 Were advised to start rituximab after
closure of randomization
19 Were excluded
4 Did not have MCL
1 Had stage I MCL
14 Stopped treatment early
A
B
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causes (13 and 9). Notably, 29 patients (10%) who 
received R-FC died while in remission, as com-
pared with 11 (4%) who received R-CHOP. Ow-
ing to the observed difference in overall survival, 
the independent data and safety monitoring com-
mittee recommended closing the R-FC group.
Hematologic toxic effects occurred more fre-
quently in the R-FC group than in the R-CHOP 
group (Table 2). Grade 1 or 2 constipation and 
neuropathy were more frequent among patients 
who received R-CHOP than among those who re-
ceived R-FC. Grade 3 or 4 infections were bal-
anced between the R-FC and R-CHOP groups, oc-
curring in 17% and 14% of patients, respectively, 
but there was a trend toward a higher frequency 
of febrile neutropenia among patients who re-
ceived R-CHOP than among those who received 
R-FC (17% vs. 11%, P = 0.052). Cardiac toxic effects 
of grade 3 or 4 were uncommon, occurring in 3 to 
4% of all patients, and the rates were similar in the 
two groups.
Owing to higher rates of hematologic toxic ef-
fects, treatment compliance was worse among pa-
tients who received R-FC: 23% of these patients 
who had a response did not complete all cycles, 
as compared with 12% of those who received 
R-CHOP and had a response. The median duration 
of induction therapy in the R-FC group was 143 
days (interquartile range, 106 to 161), as expected, 
with a median average cycle duration of 31 days; 
the median duration of induction therapy in the 
R-CHOP group was 152 days (interquartile range, 
147 to 163), as expected, with a median average 
cycle duration of 21 days.
MAINTENANCE TREATMENT
A total of 316 patients were randomly assigned to 
rituximab or interferon alfa, of whom 274 were 
included in the primary analysis (143 in the ritux-
imab group and 131 in the interferon alfa group). 
The characteristics of the patients and reasons for 
not undergoing randomization or evaluation are 
shown in Figure 1B and Table 1 and in Table S1 
in the Supplementary Appendix. Persistent cyto-
penia in 29 patients who had received R-FC pre-
cluded participation in the second randomization, 
because maintenance therapy with interferon alfa 
required adequate hematopoietic function. For the 
primary analysis, censoring due to protocol viola-
tion occurred in eight cases, all in the group that 
received interferon alfa; 6 patients switched to 
maintenance therapy with rituximab, 1 to the com-
bination of rituximab and interferon alfa, and 1 to 
radiotherapy. The median follow-up for assess-
ment of the duration of remission was 36 months 
(37 months in the rituximab group and 34 months 
in the interferon alfa group).
The remission duration was significantly lon-
ger in the rituximab group than in the interferon 
alfa group, with a 45% reduction in the risk of 
progression or death according to the primary 
analysis (hazard ratio, 0.55; 95% CI, 0.36 to 0.87; 
P = 0.01, with adjustment for interim analyses) (Fig. 
S2B in the Supplementary Appendix). At 4 years, 
58% of the patients who received rituximab were 
still in remission (50 events) versus 29% of those 
who received interferon alfa (71 events). The same 
effect was seen in the intention-to-treat analysis, 
with a 4-year rate of 57% in the rituximab group 
versus 34% in the interferon alfa group (Fig. 3A). 
Multivariable regression showed significantly dif-
ferent effects of rituximab according to the induc-
tion regimen (P = 0.04) (Table S3 in the Supple-
mentary Appendix). The influence of maintenance 
therapy with rituximab on the duration of remis-
sion was detected in patients who received R-CHOP 
but not in those who received R-FC (Fig. 3B, and 
Fig. S3A in the Supplementary Appendix).
The overall survival did not differ significantly 
between the maintenance groups: survival rates at 
4 years were 79% in the rituximab group and 67% 
in the interferon alfa group (P = 0.13) (Fig. 3C). 
Figure 1 (facing page). Randomization and Inclusion 
in the Intention-to-Treat and Primary-Analysis Populations 
for Induction and Maintenance Therapy.
Panel A shows the first randomization phase, for induc-
tion therapy. Panel B shows the second randomization 
phase, for maintenance therapy. Details regarding rea-
sons for exclusion are provided in Figure 1A in the Sup-
plementary Appendix. Patients who stopped treatment 
early (“premature stop,” defined as discontinuation of 
the induction therapy before the midterm point in the 
absence of progression or discontinuation after less than 
two thirds of the cycles had been completed in patients 
with a response) were included in the intention-to-treat 
analysis but were not included in the primary analysis. 
MCL denotes mantle-cell lymphoma; R-CHOP rituximab, 
cyclophosphamide, doxorubicin, vincristine, and pred-
nisone; and R-FC rituximab, fludarabine, and cyclophos-
phamide.
The New England Journal of Medicine 
Downloaded from nejm.org at VRIJE UNIVERSITEIT on October 29, 2013. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 367;6 nejm.org august 9, 2012526
However, there was a significant modification of 
the effect of maintenance therapy according to 
the induction regimen (P = 0.02) (Table S3 in the 
Supplementary Appendix), with a survival gain at 
4 years among the patients who received R-CHOP 
(87% in the rituximab group vs. 63% in the in-
terferon alfa group; P = 0.005) (Fig. 3D) but not 
among the patients who received R-FC (P = 0.48) 
(Fig. S3B in the Supplementary Appendix).
Toxic effects during the maintenance phase 
were more pronounced in the interferon alfa 
group, with more patients having leukocytopenia, 
thrombocytopenia, and fatigue, mostly of grade 
1 or 2, whereas rituximab was associated with 
more grade 1 or 2 infections (Table 2). Adherence 
to treatment reflected these observed differenc-
es. Overall, the median duration of maintenance 
therapy was 25 months with rituximab versus 
Table 1. Baseline Characteristics of the Patients Included in the Primary Analysis.*
Characteristic Induction Phase Maintenance Phase
Total
(N = 485)
R-FC
(N = 246)
R-CHOP
(N = 239)
Total
(N = 274)
Rituximab
(N = 143)
Interferon Alfa
(N = 131)
Age — yr
Median 70 70 70 70 69 71
Range 60–87 60–83 61–87 60–83 60–81 60–83
Male sex — no. (%) 340 (70) 178 (72) 162 (68) 193 (70) 98 (69) 95 (73)
Ann Arbor stage — no. (%)
II 30 (6) 18 (7) 12 (5) 17 (6) 7 (5) 10 (8)
III 55 (11) 30 (12) 25 (10) 34 (12) 17 (12) 17 (13)
IV 400 (82) 198 (80) 202 (85) 223 (81) 119 (83) 104 (79)
Systemic symptom — no. (%)† 182 (38) 93 (38) 89 (37) 103 (38) 57 (40) 46 (35)
ECOG performance status of 2 — no. (%)‡ 39 (8) 21 (9) 18 (8) 13 (5) 3 (2) 10 (8)
Bone-marrow involvement — no. (%) 364 (75) 182 (74) 182 (76) 202 (74) 104 (73) 98 (75)
LDH elevation — no. (%) 206 (42) 104 (42) 102 (43) 99 (36) 55 (38) 44 (34)
Median ratio of LDH activity to ULN 0.94 0.93 0.95 0.89 0.90 0.89
Median leukocyte count — ×10-9/liter 7.8 7.7 7.9 7.5 7.6 7.1
MIPI§
Median score 6.20 6.20 6.18 6.13 6.15 6.13
Low risk — no. (%) 42 (9) 24 (10) 18 (8) 26 (9) 13 (9) 13 (10)
Intermediate risk — no. (%) 201 (41) 98 (40) 103 (43) 129 (47) 64 (45) 65 (50)
High risk — no. (%) 242 (50) 124 (50) 118 (49) 119 (43) 66 (46) 53 (40)
Received R-CHOP — no. (%) NA NA NA 163 (59) 82 (57) 81 (62)
Complete remission, excluding unconfirmed 
— no. (%)
NA NA NA 119 (43) 70 (49) 49 (37)
Complete remission, including unconfirmed  
— no. (%)
NA NA NA 167 (61) 89 (62) 78 (60)
* P>0.05 for all comparisons. All variables were evaluated before the start of induction therapy. LDH denotes lactate dehydrogenase; NA not 
applicable; R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-FC rituximab, fludarabine, and cyclophospha-
mide; and ULN upper limit of the normal range.
† Systemic symptoms were defined as B symptoms in the Ann Arbor classification.
‡ Scores on the Eastern Cooperative Oncology Group (ECOG) performance status range from 0 to 5, with 0 indicating asymptomatic, 1 symp-
tomatic but ambulatory, and 2 symptomatic and in bed less than half the day; 5 indicates death.
§ The Mantle-Cell Lymphoma International Prognostic Index15 (MIPI) score is calculated from the individual patient characteristics of age, 
ECOG performance status, LDH, and leukocyte count, and its range depends on the range of these characteristics. Typical scores range 
from 4 to 10, with higher scores indicating higher-risk disease. The index classifies patients as having low-, intermediate-, or high-risk dis-
ease (see the Supplementary Appendix).
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Figure 2. Time to Treatment Failure and Overall Survival, According to 
the Induction Regimen (Intention-to-Treat Analysis).
Panel A shows the time to treatment failure among patients who were  
randomly assigned to R-FC, as compared with those who were randomly 
assigned to R-CHOP; 10 patients were excluded from the analysis. Details 
regarding reasons for exclusion are provided in Figure 1A in the Supplemen-
tary Appendix. Panel B shows overall survival among patients who were ran-
domly assigned to R-FC, as compared with those who were randomly as-
signed to R-CHOP.
7 months with interferon alfa. After 1 year, main-
tenance therapy with interferon alfa had been 
stopped in 49% of patients while they were in re-
mission, whereas after 4 years, a premature stop 
of maintenance therapy with rituximab had oc-
curred in only 28% of patients. A total of 35 pa-
tients who had a response were recommended for 
treatment with rituximab after closure of the ran-
domization for maintenance therapy.
DISCUSSION
This randomized trial, coordinated within the Eu-
ropean Mantle Cell Lymphoma Network, focused 
on older patients with mantle-cell lymphoma. Our 
results show that the fludarabine-containing in-
duction regimen was not more effective but was 
more toxic than R-CHOP. Maintenance therapy 
with rituximab almost doubled the duration of 
remission in patients who had a response to in-
duction therapy and significantly improved over-
all survival among patients who had a response 
to R-CHOP.
The outcome of the fludarabine-containing 
regimen was disappointing, given the high expec-
tations in the early 2000s. We powered the study 
to detect an absolute increase of 15 percentage 
points in the rate of complete remission with R-FC, 
assuming that more complete remissions would 
result in a longer duration of remission and better 
overall survival. The increase in early progressions 
was unexpected and resulted — in combination 
with more toxic events — in more deaths. Both 
the poor performance of the R-FC regimen itself 
and insufficient hematopoietic recovery during 
and after the induction phase were responsible 
for the fact that fewer patients who received this 
regimen were eligible for the maintenance phase. 
Similar serious toxic effects, including severe and 
sometimes fatal adverse events, were reported with 
fludarabine and cyclophosphamide in patients 
with chronic lymphocytic leukemia, and therefore, 
this regimen was not considered suitable for pa-
tients who were older than 70 years of age or who 
had two or more coexisting conditions.16,17 One 
possible criticism of the R-FC regimen in our trial 
is that it provided less dose-dense rituximab than 
did the R-CHOP regimen: one dose every 28 days 
for six cycles versus one dose every 21 days for 
eight cycles. However, we assumed that this dif-
ference would be inconsequential.
The excellent results with rituximab adminis-
tered as maintenance therapy are important. Main-
tenance therapy with rituximab showed not only 
a progression-free survival benefit but also a sig-
nificant survival advantage among patients who 
were successfully pretreated with R-CHOP. The 
protocol specification that maintenance therapy 
should continue until progression, which had been 
The New England Journal of Medicine 
Downloaded from nejm.org at VRIJE UNIVERSITEIT on October 29, 2013. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 367;6 nejm.org august 9, 2012528
based on the poor outcome of salvage treatments 
in patients with relapsed mantle-cell lymphoma, 
was followed in the majority of patients who re-
ceived maintenance therapy with rituximab. One 
might argue that the excellent outcome of main-
tenance therapy with rituximab was due solely to 
the poor performance of interferon alfa. However, 
our results with interferon alfa are better than or 
in line with those of previous trials.18,19 Moreover, 
a decrease in progression-free survival associated 
with interferon alfa has not been reported from 
any trial. Finally, we performed an intention-to-
treat analysis that included the 83 patients who 
had a response and who, before closure of the 
second randomization, were not randomly as-
signed to either maintenance regimen (none of 
whom received maintenance therapy with inter-
feron alfa), with adjustment for risk profile as 
assessed with the use of Mantle-Cell Lymphoma 
International Prognostic Index15 (see the Supple-
mentary Appendix) and category of response (Fig. 
S4 and Table S4 in the Supplementary Appendix). 
The duration of remission and overall survival time 
after a response to R-CHOP were significantly 
shorter among patients who were not assigned to 
any maintenance therapy, as compared with those 
Table 2. Toxic Events, According to Grade and Induction and Maintenance Regimens (as-Treated Analysis).*
Event
R-FC
(N = 268)
R-CHOP 
(N = 249)
Rituximab 
(N = 140)
R-FC +  
Rituximab 
(N = 59)
R-CHOP + 
Rituximab 
(N = 81)
Interferon 
Alfa
(N = 117)
R-FC +  
Interferon 
Alfa
(N = 43)
R-CHOP + 
Interferon 
Alfa
(N = 74)
percentage of patients with event of maximal grade
Anemia
Grade 1 or 2 59 68 41 53 32 42 52 36
Grade 3 or 4 20 12† 4 5 4 4 10 0
Leukocytopenia
Grade 1 or 2 18 29 49 46 51 50 37 58
Grade 3 or 4 73 59‡ 19 39 4 33§ 60 18
Lymphocytopenia
Grade 1 or 2 9 19 33 15 46 24 12 31
Grade 3 or 4 78 69‡ 45 69 27 60 81 46
Neutropenia
Grade 1 or 2 18 20 27 27 28 29 21 34
Grade 3 or 4 69 60 24 37 15 36 64 19
Thrombocytopenia
Grade 1 or 2 39 33 27 47 13 42 44 40
Grade 3 or 4 41 18¶ 6 14 1 15§ 33 4
Elevated bilirubin
Grade 1 or 2 15 8 7 8 6 8 10 7
Grade 3 or 4 1 1† 0 0 0 0 0 0
Nausea
Grade 1 or 2 36 26 11 17 6 15 21 11
Grade 3 or 4 2 1† 0 0 0 0 0 0
Constipation
Grade 1 or 2 15 28 7 8 6 7 7 7
Grade 3 or 4 2 3‡ 1 2 0 0 0 0
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Table 2. (Continued.)
Event
R-FC
(N = 268)
R-CHOP 
(N = 249)
Rituximab 
(N = 140)
R-FC +  
Rituximab 
(N = 59)
R-CHOP + 
Rituximab 
(N = 81)
Interferon 
Alfa
(N = 117)
R-FC +  
Interferon 
Alfa
(N = 43)
R-CHOP + 
Interferon 
Alfa
(N = 74)
percentage of patients with event of maximal grade
Neuropathy
Grade 1 or 2 7 36 14 3 23 14 7 18
Grade 3 or 4 1 4¶ 1 2 0 1 0 1
Fatigue
Grade 1 or 2 50 52 28 25 29 48 41 51
Grade 3 or 4 4 6 1 3 0 5‖ 10 3
Infection
Grade 1 or 2 18 31 31 36 27 17 21 14
Grade 3 or 4 17 14‡ 9 14 5 11** 12 11
Myalgia or arthralgia
Grade 1 or 2 9 12 14 15 13 19 12 22
Grade 3 or 4 0 3† 1 0 1 3 2 3
Febrile neutropenia†† 11 17 3 5 1 4 10 1
*  Adverse events were graded according to the Common Terminology Criteria for Adverse Events, version 2.0. The maximal grade is the 
highest grade of adverse event that a patient had during the treatment period; patients were included only in the percentage for the highest 
grade of event they had. The following events were associated with no significant difference between the two induction regimens or between 
the two maintenance regimens and were grade 3 or 4 in 0 to 8% of patients:  elevated creatinine, elevated aminotransferases, vomiting, 
 diarrhea, mucositis, decreased cardiac function, decreased pulmonary function, depression, allergy, weight loss, and bleeding.
†  P<0.05 for adverse events of maximal grade 0 versus grade 1 or 2 versus grade 3 or 4 for R-FC versus R-CHOP.
‡  P<0.01 for adverse events of maximal grade 0 versus grade 1 or 2 versus grade 3 or 4 for R-FC versus R-CHOP.
§  P<0.01 for adverse events of maximal grade 0 versus grade 1 or 2 versus grade 3 or 4 for rituximab versus interferon alfa.
¶  P<0.001 for adverse events of maximal grade 0 versus grade 1 or 2 versus grade 3 or 4 for R-FC versus R-CHOP. 
‖  P<0.001 for adverse events of maximal grade 0 versus grade 1 or 2 versus grade 3 or 4 for rituximab versus interferon alfa.
** P<0.05 for adverse events of maximal grade 0 versus grade 1 or 2 versus grade 3 or 4 for rituximab versus interferon alfa.
†† This adverse event is graded only within the 3 and 4 categories.
who were randomly assigned to interferon alfa 
(P = 0.002 and P<0.001, respectively). Although 
these data are not based on a randomized com-
parison, we believe that they strongly support the 
use of maintenance therapy with rituximab in 
older patients who have a response to R-CHOP.
Although our data are promising, patients still 
died from this lymphoma during the induction and 
maintenance phases. Thus far, standard first-line 
therapy for younger patients — consisting of high-
dose cytarabine, followed by autologous stem-cell 
transplantation — is generally not feasible for 
older patients. On the other hand, cytarabine 
seems to be one of the most important drugs in 
the treatment of mantle-cell lymphoma,2,20,21 and 
adapted doses appear to be feasible for older 
patients with relapsed mantle-cell lymphoma.22 
Bendamustine-based treatment has been reported 
to be active against mantle-cell lymphoma on the 
basis of a subgroup analysis in a German first-line 
trial.23 Thus, bendamustine-containing combina-
tions or molecular-targeted approaches that have 
shown high response rates among patients with 
relapsed mantle-cell lymphoma might be alterna-
tive induction regimens.22,24-26 Similarly, it may be 
attractive to combine the rituximab-based main-
tenance regimen with other drugs that have been 
shown to be active against mantle-cell lymphoma. 
However, physicians need to be aware of the po-
tential interactions between the initial therapy and 
the maintenance regimen.
In conclusion, older patients with mantle-cell 
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lymphoma who have a response to R-CHOP and 
continue to receive rituximab as maintenance ther-
apy have a longer life expectancy than those who 
receive maintenance therapy with interferon alfa.
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CT-2004-503351), the Lymphoma Research Foundation, Roche 
Pharmaceuticals, Bayer Schering Pharma, and Schering-Plough.
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Figure 3. Duration of Remission, According to the Maintenance Regimen (Intention-to-Treat Analysis).
Panel A shows the duration of remission among all patients who were randomly assigned to maintenance therapy (rituximab vs. interferon 
alfa), and Panel B the duration of remission among patients who were randomly assigned to maintenance therapy after randomization to 
R-CHOP. Panel C shows overall survival among all patients who were randomly assigned to maintenance therapy (rituximab vs. interferon 
alfa), and Panel D overall survival among patients who were randomly assigned to maintenance therapy after randomization to R-CHOP.
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